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Letters to the
Editor
Reply to the Editor:
Chronic expanding hematoma was first de-
scribed by Reid and colleagues in 19801
and reported to occur in many locations.
Although most hematomas resolve sponta-
neously, a few persist for long periods
as slowly expanding, space-occupying
masses. In the entity of chronic expanding
hematoma of the thorax, the hematoma de-
velops in the pleural space rather than in
Figure 1. Radiologic appearanc
a small pulmonary aneurysm. (R
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Complicating A Small Parenchythe pulmonary parenchyma. The hemato-
234 The Journal of Thoracic and Cardiovamas are known to expand 30 years or more
after medical or surgical treatment for tu-
berculosis. The patient usually showed me-
diastinal compression or chest wall protru-
sion. Although our patient presented with a
sudden onset of hemoptysis, she had shown
chest wall protrusion by the intrathoracic
and also extrapulmonary hematoma for
several months, which is essential for the
diagnosis of this entity.
In our patient, emergency bronchos-
copy revealed contralateral spread of he-
moptysis, which was shown in Figure 1,
A.2 Because of the almost complete com-
pression of the destroyed right lung by the
hematoma, the patient required a pneumo-
nectomy to survive.
The surgical procedure was intention-
ally delayed for several days until the left-
side spread of the hemoptysis decreased.
Median sternotomy was the way to access
the hilum directly without compressing the
small spontaneous rapidly accumulating p
nted from Interactive Cardiovascular and
, Elsaeid MM. Rapidly Accumulating S
Aneurysm, p 243-4, copyright 2004, with pmediastinum through a massive hematoma.
scular Surgery ● January 2005In the letter by Dr Sersar and associates,
their experience of pulmonary hematoma
was shown with some images. However,
the chronic expanding hematoma of the
thorax is quite different from intrapulmo-
nary hematoma in both clinical course and
presentation. Further comparative discus-
sion of treatments does not make sense
with different diseases.
Kenichi Okubo, MD
Toshihiro Okamoto, MD
Jun Isobe, MD
Yoichiro Ueno, MD
General Thoracic Surgery
Gifu National Hospital
Gifu, Japan
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Isolated mediastinal skip metastasis
in lung cancer: Is it real N2 disease?
To the Editor:
I read with great interest the study by
Keller and colleagues1 for the Eastern Co-
operative Oncology Group titled “Pro-
longed Survival in Patients With Resected
Non–Small Lung Cancer and Single-Level
N2 Disease,” published in the July 2004
issue of the Journal. The better prognosis
for single-level N2 disease than for multi-
ple N2 station involvement is a relatively
old concept. Keller and colleagues1 cor-
rectly reported that several previous studies
showed a better clinical outcome of pa-
tients with mediastinal skip metastasis than
for patients with metastases also in the hilar
nodes. The results of the Eastern Coopera-
tive Oncology Group’s trial indicated that
this advantage is limited to upper lobe tu-
mors, especially to the left upper lobe. The
authors stated that “the reason for im-
proved survival remains unclear, although
patients with skip metastases may have true
regional disease.”1
I would suggest that the scientific ex-
planation of such results may be found in
the recent studies on the sentinel node in
non–small cell lung cancer. The sentinel
node should be the first site of metastatic
involvement, because it is the first lymph
node that receives afferent lymphatic drain-
age from a primary tumor. The sentinel
lymph node is located in the mediastinum
in as many as 35% of patients; mediastinal
sentinel nodes are generally found from
upper lobe tumors, with the highest inci-
dence in the left upper lobe.2-6 Further-
more, such data are not new. An excellent
anatomic French study published in the
Journal in 1989 demonstrated that the di-
rect lymphatic drainage of lung segments
to the mediastinal nodes is quite common
for the upper lobes.7 All such reports indi-
cate that isolated involvement of mediasti-
nal sentinel nodes could be considered in
the group of N1 disease. It is not surprising
that a large, cooperative, randomized, pro-
spective trial led to such conclusions.
In conclusion, I think that the current
knowledge on the anatomic pathway of the
pulmonary lymphatic drainage indicates
Tthat the TNM classification regarding N
status is quite rough. The Eastern Cooper-
ative Oncology Group’s trial is another im-
portant confirmation that stage IIIa non–
small cell lung cancer represents an ex-
tremely heterogeneous disease stage, open
to future staging revision.
Francesco Puma, MD,
Chief of General Thoracic Surgery
Azienda Ospedaliera S. Maria
University of Perugia Medical School
Terni, Italy
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Studies of fetal cardiac bypass
To the Editor:
In their elegant studies of fetal cardiopul-
monary bypass (CPB), Carotti and col-
leagues1 use time-dated pregnant sheep of
120 to 130 days’ gestation. Indeed, in all
published studies, the preferred animals for
studying fetal CPB have been near-term
fetal sheep (mean, approximately 126
days’ gestation; term, 148 days’ gestation).
However, this age does not agree with the
now-accepted window for effective fetal
therapy in the clinical setting: 21 to 29
he Journal of Thoracic and Cardiovascularweeks’ human gestation. Therefore we pro-
pose that all investigators conduct future
fetal CPB studies at clinically relevant ges-
tational ages (83-112 days’ gestation in
sheep; see below).
This is of great import when consider-
ing the vast changes taking place in the
uteroplacental and umbilical-placental vas-
cular beds during pregnancy. For example,
the uterine weight, uterine blood flow
(UBF), and UBF per gram of uterine
weight increase significantly from 90 days
onward. Indeed, this final phase in the
growth of UBF is exponential and associ-
ated with a 3-fold increase in fetal weight
that occurs after 110 days in sheep and
beyond 30 weeks in human subjects.2 Sim-
ilarly, blood flow distribution during this
period changes substantially; nearly half
the UBF is diverted away from endometri-
um-myometrium to the placenta. These
changes reflect significant alterations in
placental vascular resistance, which affect
studies of fetal CPB. Finally, similar ges-
tational differences in physiology affect
other experimental features, such as fetal
responses to steroids.3
We would like to caution investigators,
however, against using direct gestational
equivalence (human 280 days  sheep 148
days). Differences in fetal growth rates be-
tween species can lead to large errors when
assuming direct equivalence, as we discov-
ered during our research involving early-
gestation lambs. Therefore, we developed
an equation to successfully translate gesta-
tional equivalence between species on the
basis of previous studies of sheep4 and
human5 embryos that have established the
gestational age for completion of specific
Carnegie stages of development. We trans-
lated these stages into developmental
equivalence at specific times during gesta-
tion. Using the age for each species at
equivalent Carnegie stages and assuming
full-term pregnancy, we derived a second-
degree polynomial equation:
Sheep gestation day   0.003  Human
gestation day2  0.6296  Human gesta-
tion day,
with a correlation coefficient (R2) equal to
0.9973.
Comparing our developmentally based
gestational age with that determined by di-
rect equivalence reveals a difference as
large as 14%, which can significantly affect
experimental design. For example, a 5-day
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